The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)

Jae Jin Lee, Chi Hoon Maeng, Seon Kyung Baek, Gou Young Kim, Jee Hong Yoo, Cheon Woong Choi, Yee Hyung Kim, Young Tae Kwak, Dae Hyun Kim, Young Kyung Lee, Jung Bo Kim, Si Young Kim

Research output: Contribution to journalArticlepeer-review

49 Citations (Scopus)

Abstract

We evaluated whether ribonucleotide reductase regulatory subunit M1 (RRM1) protein expression by immunohistochemistry (IHC) is a predictor of survival and response in gemcitabine-treated, advanced non-small cell lung cancer (NSCLC). We retrospectively collected 40 formalin-fixed, paraffin-embedded NSCLC tissues to investigate the protein expression of RRM1 by IHC with a purified rabbit anti-human RRM1 polyclonal antibody (ProteinTech Group, Chicago, IL, USA). RRM1 expression was positive in 14 (35%) and negative in 26 (65%) cases. Ten (25%) patients were treated as first-line and 30 (75%) patients as second-line. The median age was 61 years and M/F was 31/9. Stage IIIB/IV was 7/33 and adenocarcinoma/squamous cell carcinoma/other cell type was 20/16/4. Other characteristics, including age, gender, stage, cell type and first/second-line were not statistically different in the RRM-positive and RRM-negative groups. The overall survival of RRM1-positive groups was significantly shorter than RRM-negative groups (5.1 months vs. 12.9 months, p=0.022). The response rates of 38 out of 40 patients were assessable. Disease control rate (PR. +. SD) of the RRM1-positive groups was significantly lower than that of RRM1-negative groups (23% vs. 56%, p=0.053). In patients with gemcitabine-treated advanced NSCLC, patients with RRM1-positive tumors had worse overall survival and disease control than patients with RRM1-negative tumors.

Original languageEnglish
Pages (from-to)205-210
Number of pages6
JournalLung Cancer
Volume70
Issue number2
DOIs
Publication statusPublished - Nov 2010

Keywords

  • Chemotherapy
  • Gemcitabine
  • Immunohistochemistry
  • NSCLC
  • RRM1

Fingerprint

Dive into the research topics of 'The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)'. Together they form a unique fingerprint.

Cite this